Sharon Chung, MD

Associate Professor

Dr. Chung completed her MD (2001) at Johns Hopkins University where she was also an intern and resident (2001-04) in Internal Medicine. She was a Rheumatology Clinical Fellow at UCSF (2004-07), and joined the UCSF faculty in 2007. Dr. Chung completed a Master’s Degree in Advanced Studies in Clinical Research at UCSF (2008).

The central goal of Dr. Chung's research program is to discover genetic and epigenetic factors that influence autoimmune disease susceptibility and its manifestations, in order to identify biologic pathways involved in disease pathogenesis and potential targets for therapeutic intervention. Current projects focused on systemic lupus erythematosus (SLE) include genome-wide association studies, more focused investigations of the major histocompatilibity complex, and DNA methylation studies of specific disease manifestations. Her clinical interest is systemic vasculitis, and she directs the UCSF Vasculitis Clinic. Her research activities in vasculitis include genetic, epigenetic, and transcriptional studies of small vessel vasculitides. The UCSF Vasculitis Clinic is a member of the Vasculitis Clinical Research Consortium (VCRC), and the clinic participates in ongoing VCRC studies.
M.A.S. in Clinical Research, 2008 - Graduate Division (Advance Training in Clinical Research), University of California, San Francisco
Cert, 2006 - Medicine (Advance Training in Clinical Research), University of California, San Francisco
M.D., 2001 - School of Medicine, Johns Hopkins University
Honors and Awards
  • Ephraim Engleman Award for Excellence in Arthritis Research, University of California, San Francisco, 2011
  • Distinguished Fellow Award, American College of Rheumatology, 2007
  1. Sequence-based screening of patients with idiopathic polyarteritis nodosa, granulomatosis with polyangiitis, and microscopic polyangiitis for deleterious genetic variants in ADA2.
  2. Author Correction: A phenotypic and genomics approach in a multi-ethnic cohort to subtype systemic lupus erythematosus.
  3. A phenotypic and genomics approach in a multi-ethnic cohort to subtype systemic lupus erythematosus.
  4. The Right Frame.
  5. DNA methylation 101: what is important to know about DNA methylation and its role in SLE risk and disease heterogeneity.
  6. Genetic contributions to lupus nephritis in a multi-ethnic cohort of systemic lupus erythematous patients.
  7. Analysis of pulmonary features and treatment approaches in the COPA syndrome.
  8. Primary Angiitis of the Central Nervous System.
  9. Genome-wide profiling identifies associations between lupus nephritis and differential methylation of genes regulating tissue hypoxia and type 1 interferon responses.
  10. Rare variants, autoimmune disease, and arthritis.
  11. Current Treatment of Cryoglobulinemic Vasculitis.
  12. Genome-Wide Assessment of Differential DNA Methylation Associated with Autoantibody Production in Systemic Lupus Erythematosus.
  13. Differential methylation of interferon-related genes is associated with autoantibody production in systemic lupus erythematosus.
  14. Lupus nephritis susceptibility loci in women with systemic lupus erythematosus.
  15. MHC associations with clinical and autoantibody manifestations in European SLE.
  16. PTPN22 association in systemic lupus erythematosus (SLE) with respect to individual ancestry and clinical sub-phenotypes.
  17. CSK regulatory polymorphism is associated with systemic lupus erythematosus and influences B-cell signaling and activation.
  18. European genetic ancestry is associated with a decreased risk of lupus nephritis.
  19. Meta-analysis of genetic polymorphisms in granulomatosis with polyangiitis (Wegener's) reveals shared susceptibility loci with rheumatoid arthritis.
  20. Differential DNA methylation associated with anti-dsDNA autoantibody production in systemic lupus erythematosus.
  21. A comprehensive analysis of shared loci between systemic lupus erythematosus (SLE) and sixteen autoimmune diseases reveals limited genetic overlap.
  22. Differential genetic associations for systemic lupus erythematosus based on anti-dsDNA autoantibody production.
  23. Risk alleles for systemic lupus erythematosus in a large case-control collection and associations with clinical subphenotypes.
  24. Microscopic polyangiitis.
  25. Association of CSK Variants with Systemic Lupus Erythematosus.
  26. High-density SNP screening of the major histocompatibility complex in systemic lupus erythematosus demonstrates strong evidence for independent susceptibility regions.
  27. European population substructure correlates with systemic lupus erythematosus endophenotypes in North Americans of European descent.
  28. A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus.
  29. European population substructure is associated with mucocutaneous manifestations and autoantibody production in systemic lupus erythematosus.
  30. Kallikrein genes are associated with lupus and glomerular basement membrane-specific antibody-induced nephritis in mice and humans.
  31. Advances in the use of biologic agents for the treatment of systemic vasculitis.
  32. Specificity of the STAT4 genetic association for severe disease manifestations of systemic lupus erythematosus.
  33. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX.
  34. PTPN22: its role in SLE and autoimmunity.